Company Filing History:
Years Active: 1987
Title: The Innovations of Arthur Friedman
Introduction
Arthur Friedman is a notable inventor based in Churchville, Pennsylvania. He has made significant contributions to the field of biotechnology, particularly in the development of immunogenic substances. His work has implications for vaccine development and the treatment of viral infections.
Latest Patents
Friedman holds a patent for "Immunogenic HbsAg derived from transformed yeast." This patent describes a method for synthesizing the surface antigen protein of the human Hepatitis B virus in Saccharomyces cerevisiae. The synthesized protein is a 23,000-26,000 dalton polypeptide that is essentially free of intermolecular disulfide bonds. The patent highlights that this antigen is a poor immunogen in both animals and humans. Importantly, it presents the first method for efficiently converting the non-disulfide bonded antigen into a fully intermolecular disulfide bonded particle. This conversion enhances the immunogenicity of the antigen by approximately ten-fold, making it practical to produce hepatitis B surface antigen from microorganisms using recombinant DNA methods.
Career Highlights
Arthur Friedman is associated with Merck & Company, Inc., a leading global healthcare company. His work at Merck has allowed him to contribute to advancements in vaccine technology and immunology. His innovative approaches have paved the way for new methods in the production of vital antigens.
Collaborations
Friedman has collaborated with notable colleagues, including E Dale Lehman and William J McAleer. These collaborations have further enriched his research and development efforts in the field of biotechnology.
Conclusion
Arthur Friedman is a distinguished inventor whose work has significantly impacted the field of immunology and vaccine development. His innovative patent on the immunogenic HbsAg derived from transformed yeast showcases his contributions to science and medicine.